Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
4(36%)
Results Posted
50%(1 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_2
5
45%
Ph phase_3
2
18%
Ph phase_1
3
27%
Ph phase_4
1
9%

Phase Distribution

3

Early Stage

5

Mid Stage

3

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
3(27.3%)
Phase 2Efficacy & side effects
5(45.5%)
Phase 3Large-scale testing
2(18.2%)
Phase 4Post-market surveillance
1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

4

trials recruiting

Total Trials

11

all time

Status Distribution
Active(6)
Completed(2)
Terminated(2)
Other(1)

Detailed Status

Recruiting4
Not yet recruiting2
Completed2
Withdrawn1
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
4
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (27.3%)
Phase 25 (45.5%)
Phase 32 (18.2%)
Phase 41 (9.1%)

Trials by Status

not_yet_recruiting218%
withdrawn19%
terminated19%
completed218%
recruiting436%
unknown19%

Recent Activity

Clinical Trials (11)

Showing 11 of 11 trials
NCT03693807Phase 2

A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

Completed
NCT07094893Phase 4

Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status

Not Yet Recruiting
NCT07056777Phase 1

Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer

Recruiting
NCT06733038Phase 3

FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

Recruiting
NCT06897644Phase 3

Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

Recruiting
NCT06760117Phase 1

UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors

Recruiting
NCT06652412Phase 2

CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC

Not Yet Recruiting
NCT04668976Phase 2

A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

Unknown
NCT03069950Phase 2

Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver

Withdrawn
NCT00001495Phase 1

A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors

Completed
NCT00316433Phase 2

Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer

Terminated

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11